Introduction Previous studies have shown that primary breast cancer patients with estrogen receptor (ER)-positive status have better outcomes in terms of both overall survival and disease-free intervals (DFI). However, 25.2 % of our ER-positive patients experienced recurrence. This study aimed to define factors potentially predicting survival after first recurrence in surgically treated patients with stage I-III breast cancer. Methods We retrospectively analyzed 252 females with recurrent breast cancer who had undergone surgery and been followed at Kyoto University Hospital in Japan. Age, clinical stage, pathological stage, axillary lymph node involvement, ER status at the time of diagnosis, progesterone receptor status, human epidermal growth factor receptor 2 status, operative method, adjuvant chemotherapy, adjuvant endocrine therapy, use of trastuzumab after recurrence, site of recurrence, DFI, and time of recurrence were examined for possible influences on survival after the first recurrence.
Introduction
Breast cancer patients follow a variety of clinical courses, depending on tumor characteristics. Some relapse a few months after operation, while others may relapse many years later. Recurrent breast cancer patients usually die from their disease, but the time from recurrence to death differs markedly among these patients.
Prognostic factors are important for estimating outcomes and determining the optimal form of treatment. When a patient is considered to be at high risk for recurrence, physicians must plan follow-up and treatments carefully. Prognostic factors related to overall survival (OS) and disease-free interval (DFI) have been extensively evaluated. In addition, we previously reported that estrogen receptor (ER)-positive patients had better OS-and DFIrelated prognostic factors [1, 2] .
Breast cancer treatment is usually combined with surgery, chemotherapy, endocrine therapy, molecular-targeted therapy and/or radiation therapy. Recent progress in breast cancer treatments has benefited some patient populations. There are several reports documenting improved survival of breast cancer patients [3] . In our previous study, we described prolongation of OS over time [2] . However, 25.2 % of ER-positive patients in our prior study experienced recurrence.
We retrospectively analyzed data from 252 recurrent breast cancer patients to determine factors possibly influencing outcomes and changes in the duration of survival over time after first recurrence. We emphasize that this study was based on results from a single institution. Such a single institutional study has the advantage that patient backgrounds are homogenous and follow-up methods are consistent.
Methods

Patients
This study was approved by the Kyoto University ethics committee. From 1980 to 2005, 922 female patients with stage I-III breast cancer underwent breast surgery with axillary lymph node dissection at Kyoto University Hospital. Out of 922 total patients, 252 (27.3 %) breast cancer patients had recurrence before 31 December 2008. The characteristics of 252 patients of stage I-III with recurrence and 670 patients without recurrence are shown in Table 1 . All patients were female, and 43.7 % of the patients with recurrence were older than 55 years old and were postmenopausal. Staging of clinical stage (TNM) and pathological stage (pTNM) were determined by the UICC stage classification system. Breast-conserving surgery has been performed since 1990. As a rule, all of the patients who underwent breast-conserving surgery received radiation therapy to the conserved breast.
Most of the patients were followed at Kyoto University Hospital, and some of them were followed at Kitano Hospital, Osaka, Japan, which is an affiliate hospital of Kyoto University Hospital. More than 80 % of patients had a single recurrent organ at first recurrence, and 17.5 % of patients had more than two recurrent organs at first recurrence (Table 2) . Forty percent of patients had soft-tissue recurrence, 19.4 % of patients had bone metastasis, 17.5 % of patients had lung or pleura metastasis, and 5.2 % of patients had liver metastasis.
Pathological data
Pathological data, including the number of axillary lymph node metastasis (pN), ER status, progesterone receptor 
Treatment after recurrence
Treatment after recurrence varied for each patient. The goals of treatment for recurrent patients were prolonging life and maintaining quality of life. Considering patient's general condition, treatments were started based on the phenotype of the recurrent tumor. For hormone receptorpositive patients, endocrine therapy was applied. Drugs were chosen among aromatase inhibitors, tamoxifen, LHRH analog, high dose toremifene, or medroxyprogesterone acetate. For triple-negative tumors, chemotherapy was given. First-line palliative chemotherapy included an anthracycline or taxane. Second-line chemotherapy was mostly based on non-anthracycline non-taxane. For HER2-overexpressing tumors, trastuzumab combined with chemotherapy was given after 2000. For bone metastasis, bisphosphonates were used. If necessary, radiotherapy was added.
Statistical analysis
We statistically analyzed prognostic factors related to survival time from first recurrence to death. Survival curves were estimated with the Kaplan-Meier method. The univariate analysis was performed using the log-rank test and the univariate Cox regression analysis for estimating hazard ratios. The multivariate Cox regression analysis with the backward elimination method was used to estimate hazard ratios and to identify independent prognostic factors. The univariate logistic regression analysis was used to investigate the independence between recurrent date (period I: 1980-1994; period II: 1995-2008) and each factor: age at primary breast surgery, TNM, pTNM, pN, ER status, PR status, HER2 status, breast surgery, adjuvant endocrine therapy, adjuvant chemotherapy, site of first recurrence, use of trastuzumab after recurrence, and DFI. All reported p values are two-sided, and a value below 0.05 was considered statistically significant. All statistical analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Results
Factors related to survival after first recurrence
With the univariate analysis, pTNM (p = 0.009), pN (p = 0.024), ER status (p \ 0.001), PR status (p = 0.005), adjuvant chemotherapy (p = 0.038), the site of first recurrence (p = 0.001), DFI (p \ 0.001), and recurrent date (p \ 0.001) were related to survival after first recurrence. Meanwhile, age at the time of primary breast surgery, TNM, HER2 status, breast surgery, adjuvant endocrine therapy, and use of trastuzumab after recurrence had no relationship with survival after first recurrence (Table 3) .
Estrogen receptor status and PR status were strongly related to survival time after recurrence. The Kaplan-Meier analysis revealed that ER-positive patients showed more favorable survival rates throughout the 10 years after the first recurrence than ER-negative patients (Fig. 1a) . ER positivity was a strong predictor both in pre-and postmenopausal patients (p \ 0.001).
The site of first recurrence was significantly associated with survival after first recurrence. Patients with liver metastasis and metastases of more than two organs showed poorer survival rates than those with single metastasis of soft tissues, lung/pleura, or bone (Fig. 1b) . ER-positive patients tend to have liver, lung/pleura, or bone metastases. Otherwise, ER-negative patients tend to have shorter DFI (Table 2 ). There was no patient whose first recurrent site was the brain.
The patients with a longer DFI had better survival rates after first recurrence than those with a shorter DFI (Fig. 1c) .
Independent prognostic factors after first recurrence
With the multivariate analysis, ER status (p \ 0.001), the site of first recurrence (p \ 0.001), time of first recurrence (p \ 0.001), PR status (p = 0.031), and DFI (p = 0.033) were significant and independent factors influencing the survival after first recurrence (Table 4 ). In particular, the hazard ratio in the ER-positive patients was 0.351 [95 % confidence interval (CI) 0.228-0.540] compared with that in ER-negative patients after adjustment for the site of recurrence, time of recurrence, PR status, and DFI. Time of first recurrence was still significant on the multivariate analysis.
Chronological changes in survival after first recurrence curve
The number of patients who were recurrent in period I (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) Table 4 ). Survival after first recurrence was significantly improved from period I to period II (p \ 0.001, Fig. 2a) . From period I to period II, the median survival time was 967 days (2.65 years) and 1831 days (5.02 years), respectively. Survival after first recurrence was improved both in the ER-positive and ER-negative subgroups (Fig. 2b, c) . In the ER-positive subgroup, the median survival time was 1520 days (4.16 years) and 2569 days (7.04 years) for period I and period II, respectively (p = 0.053). In the ERnegative subgroup, the median survival time was 660 days (1.808 years) and 879 days (2.41 years) for period I and period II, respectively (p = 0.022).
Factors contributing to chronological change of survival after first recurrence
In order to determine the factors contributing to the chronological change in survival, we performed a univariate logistic regression analysis. Pathological TNM (p = 0.024), breast surgery (p \ 0.001), adjuvant chemotherapy (p = 0.014), and DFI (p \ 0.001) had a significant relationship with chronological improvement in survival ( Table 6 ). The patients in period II had an earlier stage, longer DFI, and received more breast-conserving surgery and more intravenous adjuvant chemotherapy than the patients in period I.
Discussion
Twenty to 30 % of early breast cancer patients experience recurrence [4] . The course of treatment for these patients is determined based on the Hortobagyi's decision tree [5] . When a patient is diagnosed with recurrent breast cancer, hormone-receptor status, DFI, age, and menopausal status are initially assessed. When the disease is hormoneresponsive and non-life-threatening, the patient receives first-line endocrine therapy. Thus, ER status is the first important decision-making factor. We previously reported that ER status was a favorable prognostic factor of OS and DFI [1, 2] . In this study, we showed that ER status and PR status at the time of the operation were independent predictors of survival after first recurrence (Table 4) . Although the assessment process has changed, ER positivity remained a strong predictor throughout our study period. The 5-year survival rate after the first recurrence in ER-negative patients was 27 % (95 % CI 17-37 %), while that in ER-positive patients was 54 % (95 % CI 42-64 %). This result confirmed several reports describing ER status as the best predictor of survival after first breast cancer recurrence [6] [7] [8] [9] . In our present study, HER2-positive status did not indicate a poor prognosis with statistical significance. This was due to the small number of patients with ascertained HER2 status, because HER2 assessment began in 2000. With the univariate analysis, axillary lymph node status was related to survival after first recurrence (p = 0.024). However, based on multivariate analysis, axillary lymph node status was not an independent factor determining survival after first recurrence. There were several reports that the multivariate analysis showed axillary lymph node status to be independently associated with survival after first recurrence [6, 8, 9] , while another report showed that axillary node status indicated the probability of relapse but did not influence the length of survival after relapse [7] . In this study, DFI was also an independent prognostic factor of survival after first recurrence. Clark et al. [6] and Insa et al. [8] reported that DFI provided independent information for predicting patient survival after recurrence, while Koenders et al. [9] observed no association between survival from the detection of first metastasis and DFI. Moreover, Howell et al. [7] reported that there was no significant difference between patients with receptor-positive and receptor-negative tumors in the relapse-free interval, but survival from first relapse was longer in patients with receptor-positive tumors. One of the reasons for this difference might be due to chronological changes of adjuvant treatments.
The site of initial recurrence is an important determinant for predicting survival from the time of initial recurrence. There are several reports indicating ER-positive status to be significantly associated with a higher rate of bone metastasis [6, 10, 11] . In this study, 53.1 % of patients with bone metastasis were ER-positive, and 34.7 % of patients with bone metastasis were ER-negative ( Table 2 ). The 5-year post-recurrent survival rate was 55 % (95 % CI 39-69 %) in patients whose site of first recurrence was bone, but was only 13 % (95 % CI 1-43 %) in those with the liver as first site of recurrence (Fig. 1b) , and the multivariate analysis showed the first dominant site of metastasis to be independently associated with survival after recurrence as showed by others [6, 8, 9] . In our present study, more than two metastatic sites predicted a poor outcome. Multiple metastases mean that cancer cells have disseminated extensively. Some patients develop limited numbers and sites of metastatic disease. Oligometastasis is the term describing restricted tumor metastatic capacity and is associated with a better prognosis [10] . Patients with oligometastases are sometimes curable following surgical treatment. Patients with more than two sites of organ involvement mostly deviate from this concept and are less curable. Liver metastasis is also associated with a poor prognosis, because it also means disseminated cancer cells and leads to early mortality. Even among patients with liver metastasis, the existence of multiple metastases represents a poorer prognosis after liver resection [11] .
Time of the first recurrence is one of the prognostic factors of survival after the first recurrence (Table 4) . The survival curves after the first recurrence improved from 1980-1994 to 1995-2008 (Fig. 2) . We previously reported that OS of primary breast cancer patients in our institute improved significantly from 1982-1989 to 1990-2003 [2] . The improvement of OS is suggested to reflect improvement in survival after the first recurrence.
On logistic regression analysis, breast surgery and adjuvant chemotherapy were treatment-related factors contributing to improved survival over time (Table 6 ). In view of breast surgery, partial mastectomy was applied to tumors of relatively small size and early stage breast cancer. The remnant breast after partial mastectomy generally receives radiation therapy. Radiation therapy has been reported to reduce breast cancer-related mortality [12] . Radiation therapy is suggested to affect the result in addition to breast surgery.
Adjuvant chemotherapy has dramatically changed in the past quarter of a century. Oral chemotherapy was the mainstream in the 1980s at our institution. New drugs, such as taxane, trastuzumab-combined chemotherapy, or anthracycline-containing regimens, have become available since 2000. Randomized trials have demonstrated that these drugs improve survival. We did not identify any specific drug as contributing to improved survival over time, but we assume that advances in adjuvant chemotherapy in general have all contributed to this clear trend.
As an adjuvant endocrine therapy, selective estrogen receptor modulators such as tamoxifen were approved in 1981, and third generation aromatase inhibitors have been administered since 2001 in Japan. In this study, the number of patients given aromatase inhibitors as adjuvant therapy was quite small, such that their impact on improvements over time appeared to be minimal. This supports the view that adjuvant endocrine therapy did not affect chronological change.
The kinds of treatment provided after recurrence varies with each individual. ER-negative patients usually receive Trastuzumab has also improved the survival of HER2-positive patients [13] , although our study does not significantly support this. In addition to chemotherapy or molecular-targeted therapy, wide varieties of endocrine therapy are used after recurrence in many ER-positive patients. Drugs that may benefit ER-positive patients include aromatase inhibitors, tamoxifen, LHRH analogs, high-dose toremifene, and medroxyprogesterone acetate. We document the importance of the increasing number of approved drugs allowing better survival after recurrence. The survival curve showed improvement both in ERpositive and ER-negative subgroups. Especially in the ERnegative subgroup, survival after the first recurrence increased significantly (p = 0.022). Our results differ from reports by Andre et al. [14] and Shigematsu et al. [15] . They reported that the hormone receptor-positive subgroup has better survival improvement. In our institution, adjuvant chemotherapy has changed from oral therapy to intravenous multi-therapy. On univariate logistic analysis, adjuvant chemotherapy is one of the factors contributing to chronological survival changes. Our results indicate that survival improvement has been led by the change in adjuvant chemotherapy.
Pathological TNM was a factor contributing to changes in survival over time. This prompted us to speculate that more women are undergoing breast cancer screening, including mammography, and therefore seeking treatment in earlier stages of breast cancer, which has resulted in better outcomes [16] .
Disease-free intervals were also one of the factors significantly influencing chronological change. It is reasonable to assume that DFI was prolonged because of advances in adjuvant treatments and better patient awareness of breast cancer. Prolonged DFI also impacted the observed improvement not only in survival over time, but also in the survival after first recurrence. Certain factors such as the attitudes of patients and their families, or the method of follow-up, may affect the ongoing improvement in survival. These results give us hope that survival time after the first recurrence will be even longer in the future. 
Conclusions
The series of patients examined in this study showed ERpositive status at the time of diagnosis to be associated with increased OS, DFI, and survival time after the first recurrence of breast cancer. However, the site of recurrence, PR status at the time of diagnosis, DFI, and recurrent year were also factors predicting outcomes. Survival time after the first recurrence of breast cancer has steadily increased in recent decades, significantly in ER-negative subgroups. We confirmed that advances in treatments and attitudes about breast cancer have contributed to this improvement in survival after first recurrence. 
